Program
ziltivekimab
Also written as “Ziltivekimab”, “Ziltivekimab B” and “Ziltivekimab C”.
Its studies are mostly in Renal Insufficiency, Chronic · Heart Failure · Myocardial Infarction · Coronary Artery Disease · Anemia, led by 2 companies.
Drug pageZiltivekimab: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 113 open or running | phase 3since Aug 19, 2021 | Mar 19, 2012 | Jan 29, 2027phase 3 · NCT06118281 |
| ECRI bv | 11 open or running | phase 3since Nov 28, 2025 | Nov 28, 2025 | Sep 1, 2028phase 3 · NCT07276282 |
- Named in Novo Nordisk’s own pipeline as
Ziltivekimab
, phase 3, as of Nov 5, 2026 (source).
Also a collaborator on its studies: Corvidia Therapeutics and Cardialysis.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of ECRI bv only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2019Named ziltivekimabINNProposed as its International Nonproprietary Name in WHO's List 121 · before, COR-001, MEDI5117
- Nov 28, 2025First study: phase 3 study in Coronary Artery DiseaseFirst studyNCT07276282 · 332 planned · Switzerland
Ahead
- Sep 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseNCT07276282
TargetBeta
“Interleukin-6 inhibitor; Interleukin-6 binding agent”ChEMBL 37, by rule
Other programs on IL6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olokizumabrule | R-Pharm | phase 3 | 19 |
| clazakizumab | CSL | phase 3 | 10 |
| pacibekitugrule | Novartis | phase 3 | 1 |
| isomyosaminerule | tnf-pharmaceuticals-inc | phase 2 | 1 |
Studies
The one study ECRI bv leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07276282Coronary Artery Disease · Switzerland | 3 | Recruiting | Sep 1, 2028 | 332 |
How it is read
Names in the registry
- “Ziltivekimab”, 8 entries
- “Ziltivekimab B”, 2 entries
- “Ziltivekimab C”, 2 entries
- “COR-001”, 1 entry
- “MEDI5117”, 1 entry
Conditions, from the studies’ own filings
- Renal Insufficiency, Chronic, 4 studies
- Heart Failure, 2 studies
- Myocardial Infarction, 2 studies
- Coronary Artery Disease, 1 study
- Anemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.